Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 13/20 | 0.51 |
| ▸ | OPRM1 | P35372 | 13/20 | 0.51 |
| ▸ | OPRK1 | P41145 | 12/20 | 0.51 |
| ▸ | MRGPRX2 | Q96LB1 | 2/20 | 0.46 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.45 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16126175 | 0.91 | OPRD1 (0.49) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| SCHEMBL19484944 | 0.90 | OPRD1 (0.52) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| SCHEMBL16126168 | 0.90 | OPRD1 (0.52) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| SCHEMBL16126172 | 0.88 | OPRM1 (0.46) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| SCHEMBL17472086 | 0.88 | OPRM1 (0.46) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| SCHEMBL17472081 | 0.88 | OPRD1 (0.50) | OPRD1OPRM1OPRK1MRGPRX2 | |
| SCHEMBL17472096 | 0.85 | OPRD1 (0.46) | OPRD1OPRM1OPRK1MRGPRX2 | |
| SCHEMBL19484993 | 0.84 | OPRM1 (0.42) | OPRD1OPRM1OPRK1MRGPRX2 | |
| SCHEMBL16126178 | 0.81 | OPRD1 (0.49) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| SCHEMBL19484996 | 0.81 | OPRD1 (0.49) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170296654-A1 | 6-ACETYLMORPHINE ANALOGS, AND METHODS FOR THEIR SYNTHESIS AND USE | ALERE SAN DIEGO, INC. | 2017-10-19 | — | — | US | disclosed |
| US-9694069-B2 | 6-acetylmorphine analogs, and methods for their synthesis and use | ALERE SAN DIEGO, INC. (US) | 2017-07-04 | — | — | US | disclosed |
| US-9694069-B2 | 6-acetylmorphine analogs, and methods for their synthesis and use | ALERE SAN DIEGO, INC. (US) | 2017-07-04 | — | — | US | disclosed |
| US-20160022809-A1 | 6-ACETYLMORPHINE ANALOGS, AND METHODS FOR THEIR SYNTHESIS AND USE | ALERE SAN DIEGO, INC. | 2016-01-28 | — | — | US | disclosed |
| US-20160022809-A1 | 6-ACETYLMORPHINE ANALOGS, AND METHODS FOR THEIR SYNTHESIS AND USE | ALERE SAN DIEGO, INC. | 2016-01-28 | — | — | US | disclosed |
| WO-2014152657-A1 | 6-ACETYLMORPHINE ANALOGS, AND METHODS FOR THEIR SYNTHESIS AND USE | ALERE SAN DIEGO, INC. (US) | 2014-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160022809-A1 | 6-ACETYLMORPHINE ANALOGS, AND METHODS FOR THEIR SYNTHESIS AND USE | DNPEP, CRHBP, AANAT | OPRD1 30/4885OPRM1 11/4885OPRK1 13/4885 |
| US-20170296654-A1 | 6-ACETYLMORPHINE ANALOGS, AND METHODS FOR THEIR SYNTHESIS AND USE | DNPEP, CRHBP, AANAT | OPRD1 30/4885OPRM1 11/4885OPRK1 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.